Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NiQuitin CQ

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's UK launch of smoking cessation lozenges backed by £10 mil. (approximately $14.2 mil.) marketing campaign including £5 mil. ad campaign beginning in December, firm says. Mint-flavored lozenges contain either 2 mg or 4 mg nicotine polacrilex and launched in UK pharmacies in October. A one-week supply costs roughly $24.80. Launch could pave the way for eventual product introduction in U.S. Study finding lozenges lead to higher success rate than other nicotine-replacement therapies slated for publication in March Archives of Internal Medicine...

You may also be interested in...

Glaxo NRT Promotional Campaign Targets Smokers Not Ready To Quit

GlaxoSmithKline is launching a $20 mil. ad campaign to boost the firm's lagging smoking cessation product sales following a disappointing second quarter performance

NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End

GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts